Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › TAS-102

TAS-102

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of TAS-102

12 trials tracked of TAS-102: 5 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

12Trials tracked
5Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 5 Phase 2 5 Phase 1 2
  1. Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Completed · 4 cited
  2. Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study Completed
  3. Phase 3 Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed
  4. Phase 3 Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Completed
  5. Phase 3 Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia Completed
  6. Phase 2 A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC Completed
Show 6 more trials
  1. Phase 2 SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer Completed
  2. Phase 2 Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer Completed
  3. Phase 2 TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Completed
  4. Phase 2 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) Completed
  5. Phase 1 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma Completed
  6. Phase 1 A Phase I Study of TAS-102 in Solid Tumors Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.